Review: Controversies in Prostate Cancer Screening
October 10, 2024
Department of Urology faculty including Benjamin Davies, MD, and Bruce Jacobs, MD, MPH, along with former fellow Daisy Obiora, MD, and former resident Oluwaseun Orikogbo, MD, explored the trends in recommendations and new innovations in adjunctive testing for prostate cancer screening in a recent review published online ahead of print in the Journal of Urologic Oncology. They review Prostate-Specific Antigen (PSA) testing, shifting recommendations, the impact of active surveillance on patient well-being, and other methods of screening and imaging.
Ultimately, the team stated that screening for prostate cancer remains controversial.
"There are well-founded concerns of overtreatment in many populations of men. The incorporation of mp-MRI, refined biopsy techniques, biomarker testing, and active surveillance in men diagnosed with low-risk disease have mitigated many of these harms. As more evidence becomes available, it is possible that more personalized, risk based, organized screening recommendations incorporating adjunct technologies will be available."1
View the full article.
Reference
1. Obiora D, Orikogbo O, Davies BJ, Jacobs BL. Controversies in prostate cancer screening. Urol Oncol. 2024 Aug 9:S1078-1439(24)00534-9. doi: 10.1016/j.urolonc.2024.06.022. Epub ahead of print. PMID: 39127529.
